Eli Lilly Acquires Centessa Pharmaceuticals for Up to $7.8 Billion

Eli Lilly & Co. has announced its agreement to acquire Centessa Pharmaceuticals Plc for up to $7.8 billion. The deal includes an upfront payment of $6.3 billion, equating to $38 per share, which represents a 38% premium over Centessa's closing price prior to the announcement. Additionally, Lilly may pay up to $1.5 billion contingent on the approval of Centessa's drugs by the U.S. Food and Drug Administration (FDA). The transaction is expected to close in the third quarter of 2026, pending regulatory approval.

New York Times

Centessa is focused on developing a new class of treatments targeting orexin, a brain molecule that regulates the sleep-wake cycle. Its lead drug, ORX750, is currently in mid-stage trials for narcolepsy and idiopathic hypersomnia, conditions characterized by excessive daytime sleepiness. Analysts estimate that the market for narcolepsy drugs could reach between $15 billion and $20 billion if a significant portion of patients seek treatment. The potential for these drugs extends beyond narcolepsy, with applications for conditions such as Alzheimer's disease and depression.

CNBCBoston GlobeNew York TimesBloomberg

This acquisition marks a strategic move for Eli Lilly, which has been diversifying its portfolio beyond its successful weight-loss medications, Zepbound and Mounjaro. The company has been actively pursuing acquisitions to bolster its neuroscience division, having recently acquired Orna Therapeutics and Ventyx Biosciences. Lilly's CEO, Dave Ricks, emphasized the importance of this acquisition, stating, "It's the kind of thing we should be doing to really affect millions and millions of people, potentially, who suffer from neuroscience conditions like wakefulness and sleep."

CNBC

Following the announcement, Centessa's stock surged by approximately 45%, while Eli Lilly's shares rose about 3%. Analysts have noted that while the premium offered by Lilly is modest, it reflects a growing interest in the sleep disorder market. Competitors such as Takeda Pharmaceuticals and Alkermes are also developing orexin-targeting drugs, with Takeda's drug currently under FDA review.

BloombergNew York TimesCNBCReuters

Despite the optimistic outlook for the acquisition, some analysts caution that Centessa's lead drug may not receive FDA approval until 2028. The competitive landscape remains dynamic, with other companies potentially vying for market share in the emerging field of orexin-based therapeutics. As Lilly continues to expand its pipeline, the success of this acquisition will depend on the timely approval and market acceptance of Centessa's treatments.

Bloomberg

• "We see a broader potential for this pathway... when your sleep is disturbed or your wakefulness is disturbed, it causes a problem." — Dave Ricks, CEO of Eli Lilly

CNBC

• "Driven by a bold vision, our team has advanced an innovative portfolio... to lead a new era of orexin-based therapeutics." — Mario Alberto Accardi, CEO of Centessa Pharmaceuticals

Boston Globe

This acquisition positions Eli Lilly to potentially lead in a new therapeutic area, addressing significant unmet needs in sleep disorders and related neurological conditions.

Bloomberg